Using the latest techniques and technology for LASIK laser vision correction, our experienced surgeons achieve outstanding results at our LASIK eye care and eye surgery center.Read More »
Our cataract specialists can explain all the best treatments for improving your vision, including the revolutionary Custom LASER Cataract Surgery.Read More »
Turn back time with the help of our trained surgeons. AIO offers the latest treatments and products to refresh, restore and retain a beautiful you.Read More »
Tour our Surgery Center
Check out our Photo Gallery!
HAPPY THANKSGIVING! Our Wheeling office is open on Wednesday, Nov 23. On Thursday, Nov 24 & Friday, Nov 25 all offices will be closed.
AIO will be conducting the Genentech OMASPECT clinical trial in 2017. OMASPECT is the open-label extension of the Genentech CHROMA clinical trial, which is investigating a novel intravitreal treatment, lampalizumab, for dry age-related macular degeneration with geographic atrophy (GA). Lampalizumab is designed to inhibit complement factor D, a key component in complement pathway that is implicated in the progression of GA. Our research department and our patients are excited to be a part of this groundbreaking clinical trial, which is the largest to date for this orphan indication.
Lisa Cibik, MD, FACS and John Nairn, MD, leading cataract surgeons at AIO, were the first surgeons in Western Pennsylvania to implant the FDA approved Symphony Multifocal Toric intraocular lens (IOL) that provides cataract patients with an extended depth-of-focus and astigmatism correction. Traditional monofocal IOLs have been limited to improving distance vision. The Symfony IOL improves visual acuity at close, intermediate and far ranges and, therefore, may reduce the need for patients to wear contact lenses or glasses after cataract surgery. To find out if you are good candidate for the Tecnis Symfony IOL, call 1-800-246-1000 today.
John Nairn, MD, Director of the Glaucoma Service at AIO, now offer the iStent® Complete Procedure. Implanted at the time of cataract surgery the iStent Trabecular Micro-bypass is clinically proven to reduce eye pressure in adult patients with both cataracts and mild-to-moderate open-angle glaucoma. iStent is not only the smallest medical implant known to be implanted in the human body–it also started a revolution in glaucoma surgery and treatment as the first Micro-Invasive Glaucoma Surgery (MIGS) device approved by the FDA. In a U.S. pivotal trial, iStent was shown to be effective in decreasing IOP, with an excellent safety profile, few complications, and fast recovery time2. Today, iStent has been implanted in over 100,000 eyes around the world.